Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2009 | 12-2008 | 12-2007 | 12-2006 | 12-2005 | |
| Sales | 25,814 | 27,496 | 30,542 | 32,985 | 30,749 |
| Cost of Goods | 6,460 | 7,582 | 9,017 | 10,029 | 9,858 |
| Gross Profit | 19,354 | 19,914 | 21,525 | 22,956 | 20,891 |
| Operating Expenses | 21,410 | 26,602 | 25,901 | 23,704 | 23,031 |
| Operating Income | -1,596 | -6,106 | -4,359 | -719 | -1,282 |
| Interest Expense | 66 | 5 | 30 | 113 | 185 |
| Other Income | 256 | 211 | 430 | -527 | 95 |
| Pre-tax Income | -1,406 | -5,900 | -3,959 | -1,359 | -1,372 |
| Income Tax | 95 | 234 | 332 | 152 | 79 |
| Net Income Continuous | -1,501 | -6,134 | -4,291 | -1,511 | -1,451 |
| Net Income Discontinuous | N/A | -332 | -735 | -3,262 | -568 |
| Net Income | $-1,501 | $-6,466 | $-5,026 | $-4,773 | $-2,019 |
| EPS Basic Total Ops | -899.55 | -3,598.20 | -2,698.65 | -2,698.65 | -1,199.40 |
| EPS Basic Continuous Ops | -773.48 | -3,298.35 | -2,398.80 | -899.55 | -899.55 |
| EPS Basic Discontinuous Ops | N/A | -299.85 | -299.85 | -1,799.10 | -299.85 |
| EPS Diluted Total Ops | -899.55 | -3,598.20 | -2,698.65 | -2,698.65 | -1,199.40 |
| EPS Diluted Continuous Ops | -773.48 | -3,298.35 | -2,398.80 | -899.55 | -899.55 |
| EPS Diluted Discontinuous Ops | N/A | -299.85 | -299.85 | -1,799.10 | -299.85 |
| EBITDA(a) | $1,597 | $-3,005 | $-427 | $3,606 | $2,442 |